Moleculin Biotech, Inc. (NASDAQ: MBRX) is “One to Watch”
Oncology pipeline features significant safety/efficacy advantages Lead candidate poised for FDA acceleration due to significant unmet need in AML Broad-spectrum applicability of WP1066 & WP1122 portfolios of molecules For preclinical oncology biopharma Moleculin Biotech, Inc. (NASDAQ: MBRX), the quest to deliver potentially revolutionary anti-cancer drugs to the market is enkindled by a close association with The University of Texas MD Anderson Cancer Center. This institution’s stated mission is nothing less than to make “cancer history,” and eliminate cancer on a global scale. Truly an American success story to be proud of, MD Anderson is one of the largest cancer centers…







